和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

已收盘 04-22 16:08:12

7.070

+0.230

+3.36%

最高7.290	最低6.790	成交量914.90万
今开6.790	昨收6.840	日振幅7.31%
总市值48.01亿	流通市值48.01亿	总股本6.79亿
成交额6,436万	换手率1.35%	流通股本6.79亿
市净率2.31	ROE1.44%	每股收益0.05
52周最高8.980	52周最低2.730	市盈率149.37
股息0.00	股息收益率0.00	ROA-0.64%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":7.07,"timestamp":1745309292015,"preClose":6.84,"halted":0,"volume":9149000,"delay":0,"floatShares":679000000,"shares":679000000,"eps":0.047332148171133785,"marketStatus":"已收盘","change":0.23,"latestTime":"04-22 16:08:12","open":6.79,"high":7.29,"low":6.79,"amount":64355506,"amplitude":0.073099,"askPrice":7.15,"askSize":6000,"bidPrice":7.07,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":0.04241125884178271,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":5,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":6.84,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":2.013718,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2529271375","title":"和誉-B(02256)4月22日斥资141.19万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529271375","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529271375?lang=zh_cn&edition=full","pubTime":"2025-04-22 18:25","pubTimestamp":1745317516,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2025年4月22日斥资141.19万港元回购股份20万股，每股回购价格为6.9-7.23港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2529684325","title":"和誉-B04月22日主力净流入363万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529684325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529684325?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:15","pubTimestamp":1745309710,"startTime":"0","endTime":"0","summary":"04月22日, 和誉-B股价涨3.36%，报收7.07元，成交金额6435万元，换手率1.35%，振幅7.31%，量比2.01。和誉-B今日主力资金净流入363万元，上一交易日主力净流出0万元。该股近5个交易日上涨2.93%，主力资金累计净流入664万元；近20日主力资金累计净流出4195万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170509a6c3899e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422170509a6c3899e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2529631674","title":"和誉-B盘中异动 下午盘快速上涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529631674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529631674?lang=zh_cn&edition=full","pubTime":"2025-04-22 13:31","pubTimestamp":1745299870,"startTime":"0","endTime":"0","summary":"2025年04月22日下午盘13时31分，和誉-B股票出现波动，股价大幅拉升5.26%。和誉-B股票所在的生物技术行业中，整体涨幅为5.14%。和誉-B公司简介：和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042213311094ddab1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042213311094ddab1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2527247000","title":"和誉-B(02256)4月16日斥资405.62万港元回购60万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2527247000","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527247000?lang=zh_cn&edition=full","pubTime":"2025-04-16 22:59","pubTimestamp":1744815577,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2025年4月16日，该公司斥资405.62万港元回购60万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2527610664","title":"和誉-B04月15日主力净流出170万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2527610664","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527610664?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:16","pubTimestamp":1744704975,"startTime":"0","endTime":"0","summary":"04月15日, 和誉-B股价跌0.56%，报收7.16元，成交金额2856万元，换手率0.58%，振幅7.22%，量比0.51。和誉-B今日主力资金净流出170万元，上一交易日主力净流入517万元。该股近5个交易日上涨13.05%，主力资金累计净流出756万元；近20日主力资金累计净流出1906万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415171347a6bb0459&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415171347a6bb0459&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2527186921","title":"和誉-B04月14日主力净流入517万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186921","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527186921?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:15","pubTimestamp":1744618550,"startTime":"0","endTime":"0","summary":"04月14日, 和誉-B股价涨5.42%，报收7.20元，成交金额3202万元，换手率0.66%，振幅5.86%，量比0.47。和誉-B今日主力资金净流入517万元，上一交易日主力净流出359万元。该股近5个交易日上涨16.32%，主力资金累计净流出575万元；近20日主力资金累计净流出1778万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414170800a4584a2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414170800a4584a2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2518756257","title":"和誉-B午前涨超6% 机构指公司年内开始有望迎来密集收获","url":"https://stock-news.laohu8.com/highlight/detail?id=2518756257","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518756257?lang=zh_cn&edition=full","pubTime":"2025-03-11 11:55","pubTimestamp":1741665300,"startTime":"0","endTime":"0","summary":"　　和誉-B午前上涨6.52%，现报7.84港元，成交额2590.26万港元。　　中金发布研报称，由于和誉-B创新管线进展顺利，2025年开始有望迎来密集收获，该行上调2025年净利润预测65.7%至4，473万元，并引入2026年净利润预测3.2亿元。根据公司公告，依帕戈替尼220mg BID组在ICI和mTKIs经治的FGF19+HCC中ORR为44.8%，联合阿替利珠单抗治疗FGF19+HCC的ORR 为50%，该行认为单药及联用方案均体现亮眼的有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-11/doc-inepfzsr5624303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","02256","BK1161"],"gpt_icon":0},{"id":"2518737756","title":"港股异动 | 和誉-B(02256)盘中涨超5% 机构指公司年内开始有望迎来密集收获 目前现金充裕","url":"https://stock-news.laohu8.com/highlight/detail?id=2518737756","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518737756?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:24","pubTimestamp":1741659899,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B盘中涨超5%，截至发稿，涨5.43%，报7.76港元，成交额1167.91万港元。中金发布研报称，由于和誉-B创新管线进展顺利，2025年开始有望迎来密集收获，该行上调2025年净利润预测65.7%至4,473万元，并引入2026年净利润预测3.2亿元。截至2024年末，公司现金及银行结余为19.59亿元，该行认为公司目前现金充裕，未来有望持续支持公司研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2518753262","title":"和誉-B盘中异动 股价大涨5.16%报7.740港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518753262","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518753262?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:21","pubTimestamp":1741659667,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘10时21分，和誉-B股票出现波动，股价急速拉升5.16%。截至发稿，该股报7.740港元/股，成交量149.4万股，换手率0.22%，振幅7.34%。资金方面，该股资金流入484.286万港元，流出402.83万港元。最近的财报数据显示，该股实现营业收入5.44亿港元，净利润3,056.24万港元，每股收益0.0432港元，毛利5.44亿港元，市盈率172.11倍。和誉-B股票所在的生物技术行业中，整体涨幅为0.76%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503111021079640d967&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503111021079640d967&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2518244819","title":"和誉-B(02256)3月10日斥资220.66万港元回购30万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2518244819","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518244819?lang=zh_cn&edition=full","pubTime":"2025-03-10 18:56","pubTimestamp":1741604189,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2025年3月10日该公司斥资220.66万港元回购30万股，回购价格为每股7.25-7.65港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2518125322","title":"中金：维持和誉-B(02256)“跑赢行业”评级 升目标价至9.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518125322","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518125322?lang=zh_cn&edition=full","pubTime":"2025-03-10 17:13","pubTimestamp":1741597995,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持和誉-B“跑赢行业”评级，升目标价36.1%至9.2港元。由于公司创新管线进展顺利，2025年开始有望迎来密集收获，该行上调2025年净利润预测65.7%至4,473万元，并引入2026年净利润预测3.2亿元。截至2024年末，公司现金及银行结余为19.59亿元，该行认为公司目前现金充裕，未来有望持续支持公司研发。口服PD-L1 ABSK043 ESMO-Asia 2024读出具竞争力的I期数据根据公司公告，在49名可评估初治IO患者的评估组中，ABSK043 ORR为20.4%，DCR为57.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256"],"gpt_icon":0},{"id":"2518219151","title":"和誉-B03月10日遭主力抛售37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518219151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518219151?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:16","pubTimestamp":1741594582,"startTime":"0","endTime":"0","summary":"03月10日, 和誉-B股价跌3.16%，报收7.36元，成交金额2964万元，换手率0.59%，振幅6.97%，量比0.45。和誉-B今日主力资金净流出37万元，上一交易日主力净流出282万元。该股近5个交易日上涨15.51%，主力资金累计净流入166万元；近20日主力资金累计净流出572万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170252a269bb0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170252a269bb0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2518299751","title":"和誉-B盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518299751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518299751?lang=zh_cn&edition=full","pubTime":"2025-03-10 14:46","pubTimestamp":1741589175,"startTime":"0","endTime":"0","summary":"2025年03月10日下午盘14时46分，和誉-B股票出现异动，股价快速跳水5.00%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。和誉-B股票所在的生物技术行业中，整体跌幅为2.44%。其相关个股中，同源康医药-B、和铂医药-B、绿竹生物-B涨幅较大，振幅较大的相关个股有同源康医药-B、来凯医药-B、科笛-B，振幅分别为35.78%、20.08%、19.70%。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031014461598a23387&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031014461598a23387&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2518754299","title":"和誉-B：24年实现盈利 25年匹米替尼有望NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2518754299","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518754299?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536000,"startTime":"0","endTime":"0","summary":"发展趋势2024 年实现首次盈利，在手现金充裕有望支持可持续研发。根据公司公告，公司2024 年实现首次盈利，主要由于收到7,000 万美元默克授权收入及100 万美元艾力斯里程碑付款。2024 年内匹米替尼国际III 期临床取得积极顶线结果，我们预计其2025 年有希望提交新药上市申请。我们预计匹米替尼有希望于2025 年在中国提交上市申请，并建议持续关注合作方行权情况。2025 年依帕戈替尼有望开启注册临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310140633a26976f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310140633a26976f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2517105371","title":"和誉-B03月07日主力净流出282万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2517105371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517105371?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:16","pubTimestamp":1741335406,"startTime":"0","endTime":"0","summary":"03月07日, 和誉-B股价跌4.76%，报收7.60元，成交金额5098万元，换手率0.98%，振幅6.89%，量比0.75。和誉-B今日主力资金净流出282万元，上一交易日主力净流入185万元。该股近5个交易日上涨26.04%，主力资金累计净流入211万元；近20日主力资金累计净流出620万元，其中净流出天数为13日。该股主力净额占比0.05%，港股市场排名2530/2653。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170727a263dfff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170727a263dfff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2517110880","title":"和誉-B：新型PRMT5*MTA抑制剂ABSK131的IND申请获中国CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517110880","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517110880?lang=zh_cn&edition=full","pubTime":"2025-03-07 08:14","pubTimestamp":1741306440,"startTime":"0","endTime":"0","summary":"　　和誉-B发布公告，2025年3月6日，上海和誉生物医药科技有限公司今日宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131的临床研究申请已获中国国家药品监督管理局药品审评中心批准。2024年12月初，其IND申请已获美国FDA 批准。　　将在晚期实体瘤患者中开展一项I期临床研究，名为“一项评估ABSK131在晚期╱ 转移性实体瘤患者中的安全性、耐受性、药代动力学和初步有效性的I期、首次人体、多中心、开放性研究”。　　约15%的实体瘤缺乏抑癌基因MTAP的表达。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-07/doc-inenuqsv0155229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CDE","BK4017","02256","MTA","BK4188","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2517508901","title":"和誉-B(02256)：新型PRMT5*MTA抑制剂 ABSK131的IND申请获中国CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517508901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517508901?lang=zh_cn&edition=full","pubTime":"2025-03-06 21:45","pubTimestamp":1741268747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，2025年3月6日，上海和誉生物医药科技有限公司今日宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131的临床研究申请已获中国国家药品监督管理局药品审评中心批准。2024年12月初，其IND申请已获美国FDA 批准。约15%的实体瘤缺乏抑癌基因MTAP的表达。PRMT5 在MTAP缺失肿瘤中表现出“合成致死”效应。近期研究显示，选择性靶向抑制PRMT5*MTA有望成为MTAP缺失肿瘤的新型治疗策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDE","BK4017","BK4188","LU2488822045.USD","MTA","BK1161","02256"],"gpt_icon":0},{"id":"2517649974","title":"和誉医药：2024年公司首次实现盈利，净利润约2,800万人民币，全年收入达5.04亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2517649974","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517649974?lang=zh_cn&edition=full","pubTime":"2025-03-06 09:10","pubTimestamp":1741223400,"startTime":"0","endTime":"0","summary":"　　和誉医药2024年度业绩电话会：公司创始人兼CEO徐耀昌介绍，2024年公司首次实现盈利，净利润约2,800万人民币，全年收入达5.04亿人民币，截至年底账上现金约19.6亿人民币。此外，ABSK011在肝癌二线治疗中ORR达44%，计划启动关键性临床试验。公司还布局了多个早期研发项目，涵盖合成致死、双抗ADC等领域，预计2025年将启动多个临床试验。财务方面，公司计划继续回购股票，回购金额不超过2亿港币，以提升股东价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2025-03-06/doc-inensmtv1112789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","02256","09939"],"gpt_icon":0},{"id":"2517400937","title":"和誉-B早盘一度涨超11% 公司首次实现年度扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2517400937","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517400937?lang=zh_cn&edition=full","pubTime":"2025-03-05 10:08","pubTimestamp":1741140480,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　和誉-B（02256）早盘一度涨超11%，截至发稿，股价上涨8.15%，现报7.43港元，成交额5090.53万港元。\n　　和誉近期公布年度业绩。财报显示，公司全年实现营业收入约5.04亿元人民币，同比大幅增长2544%；与此同时，公司录得当期归母净利润2830万元，首次实现年度扭亏为盈。据悉，2024年，和誉就其核心产品匹米替尼（Pimicotinib/ABSK021）与知名跨国药企默克达成BD交易，并由此获得7000万美元首付款。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-05/doc-inenqhur7924849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2517329519","title":"港股异动 | 和誉-B(02256)现涨超11% 公司首次实现年度扭亏为盈 再次宣布回购2亿港元回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2517329519","media":"智通财经","labels":["shareholding","buyback","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517329519?lang=zh_cn&edition=full","pubTime":"2025-03-05 09:52","pubTimestamp":1741139541,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B现涨超11%，截至发稿，涨10.77%，报7.61港元，成交额3909.85万港元。消息面上，和誉近期公布年度业绩。财报显示，公司全年实现营业收入约5.04亿元人民币，同比大幅增长2544%；与此同时，公司录得当期归母净利润2830万元，首次实现年度扭亏为盈。和誉同时公布，董事会已批准购回股份计划，动用不超过2亿港元于市场购回公司股份。截至2024年12月31日止年度，公司共购回并注销2259.4万股股份累计涉及金额6870万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0507},{"period":"1month","weight":-0.1471},{"period":"3month","weight":0.5166},{"period":"6month","weight":0.772},{"period":"1year","weight":1.3425},{"period":"ytd","weight":0.487}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司致力于发现及开发创新且差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK011是一种有效的高选择性小分子成纤维细胞生长因子受体4（FGFR4）抑制剂。ABSK091是一种分子靶向候选产品，是FGFR亚型1、2及3的高效及选择性抑制剂。该公司的产品主要用于治疗肝细胞癌（HCC）、尿路上皮癌（UC）及胃癌（GC）。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.143011},{"month":2,"riseRate":0.75,"avgChangeRate":0.046576},{"month":3,"riseRate":0.5,"avgChangeRate":0.054417},{"month":4,"riseRate":0.25,"avgChangeRate":-0.03451},{"month":5,"riseRate":0,"avgChangeRate":-0.043841},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.013147},{"month":7,"riseRate":0.666667,"avgChangeRate":0.049332},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.050943},{"month":9,"riseRate":0.666667,"avgChangeRate":0.042883},{"month":10,"riseRate":0.666667,"avgChangeRate":0.004984},{"month":11,"riseRate":0.75,"avgChangeRate":0.204437},{"month":12,"riseRate":0,"avgChangeRate":-0.093315}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}